{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T18:51:38Z","timestamp":1780944698534,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,18]],"date-time":"2015-04-18T00:00:00Z","timestamp":1429315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s00702-015-1400-x","type":"journal-article","created":{"date-parts":[[2015,4,17]],"date-time":"2015-04-17T00:23:54Z","timestamp":1429230234000},"page":"45-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Psychosis in Parkinson\u2019s disease: identification, prevention and treatment"],"prefix":"10.1007","volume":"123","author":[{"given":"Johannes","family":"Levin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkomiet","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter U.","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,18]]},"reference":[{"key":"1400_CR1","unstructured":"Bizzarri JV, Giupponi G, Maniscalco I, Schroffenegger P, Conca A, Kapfhammer HP (2015) Parkinson\u2019s disease and psychoses. Neuropsychiatr. (Epub ahead of print)"},{"key":"1400_CR2","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.parkreldis.2013.06.005","volume":"19","author":"FJ Carod-Artal","year":"2013","unstructured":"Carod-Artal FJ, Mesquita HM, Ziomkowski S, Martinez-Martin P (2013) Burden and health-related quality of life among caregivers of Brazilian Parkinson\u2019s disease patients. Parkinsonism Relat Disord 19:943\u2013948. doi: 10.1016\/j.parkreldis.2013.06.005","journal-title":"Parkinsonism Relat Disord"},{"key":"1400_CR3","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/mds.21596","volume":"22","author":"KR Chaudhuri","year":"2007","unstructured":"Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH (2007) The metric properties of a novel non-motor symptoms scale for Parkinson\u2019s disease: results from an international pilot study. Mov Disord 22:1901\u20131911","journal-title":"Mov Disord"},{"key":"1400_CR4","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson disease: a review. JAMA 311:1670\u20131683. doi: 10.1001\/jama.2014.3654","journal-title":"JAMA"},{"key":"1400_CR5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C (2014) Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383:533\u2013540. doi: 10.1016\/S0140-6736(13)62106-6","journal-title":"Lancet"},{"key":"1400_CR6","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mds.21875","volume":"23","author":"HH Fernandez","year":"2008","unstructured":"Fernandez HH, Aarsland D, F\u00e9nelon G, Friedman JH, Marsh L, Tr\u00f6ster AI, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG (2008) Scales to assess psychosis in Parkinson\u2019s disease: critique and recommendations. Mov Disord 23:484\u2013500. doi: 10.1002\/mds.21875","journal-title":"Mov Disord"},{"key":"1400_CR7","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/0897190011426556","volume":"24","author":"JH Friedman","year":"2011","unstructured":"Friedman JH (2011) Atypical antipsychotic drugs in the treatment of Parkinson\u2019s disease. J Pharm Pract 24:534\u2013540. doi: 10.1177\/0897190011426556","journal-title":"J Pharm Pract"},{"key":"1400_CR8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1179\/1743132814Y.0000000418","volume":"37","author":"RL Gama","year":"2015","unstructured":"Gama RL, de Bruin VM, de Bruin PF, T\u00e1vora DG, Lopes EM, Jorge IF, Bittencourt LR, Tufik S (2015) Risk factors for visual hallucinations in patients with Parkinson\u2019s disease. Neurol Res 37:112\u2013116. doi: 10.1179\/1743132814Y.0000000418","journal-title":"Neurol Res"},{"key":"1400_CR9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-0034-1367014","volume":"47","author":"JA Godschalx-Dekker","year":"2014","unstructured":"Godschalx-Dekker JA, Siegers HP (2014) Reduction of parkinsonism and psychosis with mirtazapine: a case report. Pharmacopsychiatry 47:81\u201383. doi: 10.1055\/s-0034-1367014","journal-title":"Pharmacopsychiatry"},{"key":"1400_CR10","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","volume":"43","author":"CG Goetz","year":"1993","unstructured":"Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson\u2019s disease. Neurology 43:2227\u20132229","journal-title":"Neurology"},{"key":"1400_CR11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/mds.21198","volume":"22","author":"CG Goetz","year":"2007","unstructured":"Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N (2007) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 22:41\u201347","journal-title":"Mov Disord"},{"key":"1400_CR12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11940-013-0281-2","volume":"16","author":"JG Goldman","year":"2014","unstructured":"Goldman JG, Holden S (2014) Treatment of psychosis and dementia in Parkinson\u2019s disease. Curr Treat Options Neurol 16:281. doi: 10.1007\/s11940-013-0281-2","journal-title":"Curr Treat Options Neurol"},{"issue":"3","key":"1400_CR13","doi-asserted-by":"crossref","first-page":"e91545","DOI":"10.1371\/journal.pone.0091545","volume":"9","author":"N Hack","year":"2014","unstructured":"Hack N, Fayad SM, Monari EH, Akbar U, Hardwick A, Rodriguez RL, Malaty IA, Romrell J, Shukla AA, McFarland N, Ward HE, Okun MS (2014) An eight-year clinic experience with clozapine use in a Parkinson\u2019s disease clinic setting. PLoS ONE 9(3):e91545. doi: 10.1371\/journal.pone.0091545","journal-title":"PLoS ONE"},{"key":"1400_CR14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","volume":"13","author":"A Hasan","year":"2012","unstructured":"Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, M\u00f6ller HJ, World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia (2012) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13:318\u2013378","journal-title":"World J Biol Psychiatry"},{"key":"1400_CR15","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.parkreldis.2013.06.006","volume":"19","author":"A Hassan","year":"2013","unstructured":"Hassan A, Wu SS, Schmidt P, Dai Y, Simuni T, Giladi N, Bloem BR, Malaty IA, Okun MS, Investigators NPF-QII (2013) High rates and the risk factors for emergency room visits and hospitalization in Parkinson\u2019s disease. Parkinsonism Relat Disord 19:949\u2013954. doi: 10.1016\/j.parkreldis.2013.06.006","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"1400_CR16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","volume":"35","author":"OD Howes","year":"2009","unstructured":"Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III\u2014the final common pathway. Schizophr Bull 35(3):549\u2013562. doi: 10.1093\/schbul\/sbp006","journal-title":"Schizophr Bull"},{"key":"1400_CR17","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","volume":"158","author":"S Kapur","year":"2001","unstructured":"Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158:360\u2013369","journal-title":"Am J Psychiatry"},{"key":"1400_CR18","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/mds.25003","volume":"27","author":"AH Lee","year":"2012","unstructured":"Lee AH, Weintraub D (2012) Psychosis in Parkinson\u2019s disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord 27:858\u2013863. doi: 10.1002\/mds.25003","journal-title":"Mov Disord"},{"key":"1400_CR19","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, L\u00e4ssig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951\u2013962. doi: 10.1016\/S0140-6736(13)60733-3","journal-title":"Lancet"},{"key":"1400_CR20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00213-005-0170-9","volume":"183","author":"Z Li","year":"2005","unstructured":"Li Z, Ichikawa J, Huang M, Prus AJ, Dai J, Meltzer HY (2005) ACP-103, a 5-HT2A\/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology 183:144\u2013153","journal-title":"Psychopharmacology"},{"key":"1400_CR21","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00228-014-1772-0","volume":"70","author":"UC Lutz","year":"2014","unstructured":"Lutz UC, Sirfy A, Wiatr G, Altpass D, Farger G, Gasser T, Karle KN, Batra A (2014) Clozapine serum concentrations in dopamimetic psychosis in Parkinson\u2019s disease and related disorders. Eur J Clin Pharmacol 70:1471\u20131476. doi: 10.1007\/s00228-014-1772-0","journal-title":"Eur J Clin Pharmacol"},{"key":"1400_CR22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0079-6123(08)00909-6","volume":"172","author":"HY Meltzer","year":"2008","unstructured":"Meltzer HY, Huang M (2008) In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 172:177\u2013197. doi: 10.1016\/S0079-6123(08)00909-6","journal-title":"Prog Brain Res"},{"key":"1400_CR23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.schres.2012.07.029","volume":"141","author":"HY Meltzer","year":"2012","unstructured":"Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, Hacksell U (2012) Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2\u00a0mg\/day, but does not enhance efficacy of haloperidol, 2\u00a0mg\/day: comparison with reference dose risperidone, 6\u00a0mg\/day. Schizophr Res 141:144\u2013152. doi: 10.1016\/j.schres.2012.07.029","journal-title":"Schizophr Res"},{"issue":"4","key":"1400_CR24","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1471-4159.1990.tb03162.x","volume":"55","author":"EK Perry","year":"1990","unstructured":"Perry EK, Marshall E, Kerwin J, Smith CJ, Jabeen S, Cheng AV, Perry RH (1990) Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 55(4):1454\u20131456","journal-title":"J Neurochem"},{"key":"1400_CR25","first-page":"260485","volume":"2014","author":"M Rodr\u00edguez-Violante","year":"2014","unstructured":"Rodr\u00edguez-Violante M, Cervantes-Arriaga A, Vel\u00e1zquez-Osuna S, Llorens-Arenas R, Calder\u00f3n-Fajardo H, Pi\u00f1a-Fuentes D, Martinez-Martin P (2014) Independent Validation of the SEND-PD and Correlation with the MDS-UPDRS Part IA. Parkinsons Dis 2014:260485. doi: 10.1155\/2014\/260485","journal-title":"Parkinsons Dis"},{"key":"1400_CR26","doi-asserted-by":"crossref","first-page":"e003533","DOI":"10.1136\/bmjopen-2013-003533","volume":"3","author":"H Sawada","year":"2013","unstructured":"Sawada H, Oeda T (2013) Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson\u2019s disease (EDAP). BMJ Open 3:e003533. doi: 10.1136\/bmjopen-2013-003533","journal-title":"BMJ Open"},{"key":"1400_CR27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1471-2377-13-145","volume":"13","author":"H Sawada","year":"2013","unstructured":"Sawada H, Oeda T, Yamamoto K, Umemura A, Tomita S, Hayashi R, Kohsaka M, Kawamura T (2013) Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study. BMC Neurol 13:145. doi: 10.1186\/1471-2377-13-145","journal-title":"BMC Neurol"},{"issue":"Suppl 3","key":"1400_CR28","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord 26(Suppl 3):S42\u2013S80. doi: 10.1002\/mds.23884","journal-title":"Mov Disord"},{"key":"1400_CR29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/YCT.0b013e3181c18a3d","volume":"26","author":"S Ueda","year":"2010","unstructured":"Ueda S, Koyama K, Okubo Y (2010) Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT 26:111\u2013115. doi: 10.1097\/YCT.0b013e3181c18a3d","journal-title":"J ECT"},{"key":"1400_CR30","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.pnpbp.2011.05.003","volume":"35","author":"C Usui","year":"2011","unstructured":"Usui C, Hatta K, Doi N, Kubo S, Kamigaichi R, Nakanishi A, Nakamura H, Hattori N, Arai H (2011) Improvements in both psychosis and motor signs in Parkinson\u2019s disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry 35:1704\u20131708. doi: 10.1016\/j.pnpbp.2011.05.003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1400_CR31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.parkreldis.2012.10.022","volume":"19","author":"T Voss","year":"2013","unstructured":"Voss T, Bahr D, Cummings J, Mills R, Ravina B, Williams H (2013) Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson\u2019s disease psychosis. Parkinsonism Relat Disord 19:295\u2013299. doi: 10.1016\/j.parkreldis.2012.10.022","journal-title":"Parkinsonism Relat Disord"},{"key":"1400_CR32","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archneurol.2011.139","volume":"68","author":"D Weintraub","year":"2011","unstructured":"Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC (2011) Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol 68:899\u2013904. doi: 10.1001\/archneurol.2011.139","journal-title":"Arch Neurol"},{"key":"1400_CR33","first-page":"393","volume":"45","author":"PJ Whitehouse","year":"1987","unstructured":"Whitehouse PJ (1987) Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson\u2019s disease and Alzheimer\u2019s disease. Adv Neurol 45:393\u2013397","journal-title":"Adv Neurol"},{"issue":"7 Suppl 3","key":"1400_CR34","first-page":"S10","volume":"52","author":"EC Wolters","year":"1999","unstructured":"Wolters EC (1999) Dopaminomimetic psychosis in Parkinson\u2019s disease patients: diagnosis and treatment. Neurology 52(7 Suppl 3):S10\u2013S13","journal-title":"Neurology"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-015-1400-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-015-1400-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-015-1400-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:30:32Z","timestamp":1559089832000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-015-1400-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,18]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["1400"],"URL":"https:\/\/doi.org\/10.1007\/s00702-015-1400-x","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,18]]}}}